Macrophage Therapeutics, a newly created business unit of Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), hosted a conference where data was presented using Manocept™ platform compound, tilmanocept, that was generated by independent academic collaborators with expertise in the HIV/AIDS, cancer, tuberculosis (TB), rheumatoid arthritis and cardiovascular disease therapeutic areas. Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) belongs to Healthcare sector. Its weekly performance is 21.09%. On last trading day company shares … Continue reading Stocks to Watch: Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB), Energy XXI Ltd (NASDAQ:EXXI), Astro-Med, Inc. (NASDAQ:ALOT), Intercontinental Hotels Group plc (NYSE:IHG), Skechers (NYSE:SKX)